Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 27%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group is a leading medical technology company with FDA-approved products for organ transplantation and a potential for clinical trial-driven growth. While the company may face operating expenses and competition challenges, its strong performance in recent years and expansion efforts position it well for continued success. Surgeons have expressed positive views on its innovative products, although they have raised concerns about potential competition in the market.

Bears say

TransMedics Group is facing declining share count estimates, leading to a decrease in estimated EPS for fiscal year 2026 and 2027. Additionally, the stock is currently trading below its 2-year and 5-year averages, indicating potential undervaluation. The company is facing competition from XVIVO in the organ preservation market, and its potential entry into the organ procurement market faces opposition and potential challenges. Overall, TransMedics Group is facing financial and market challenges that could impact its future growth potential.

TMDX has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 27% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 11 analysts, TMDX has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $118.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $118.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.